PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients.
EQS-News: ABIVAX / Key word: Conference
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th.
EQS-News: ABIVAX / Key word(s): ConferenceAbivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO) 13.02.2024 / 08:30 CET/CESTThe issuer is solely responsible for the content o.
Abivax Announces Presentation Of Four Abstracts For Obefazimod In Ulcerative Colitis And Sponsorship Of Scientific Symposium At The 19Th Congress Of E menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.